Upcoming Dividend • Apr 17
Upcoming dividend of €2.10 per share Eligible shareholders must have bought the stock before 24 April 2026. Payment date: 11 May 2026. The company is not currently making a profit and is not cash flow positive. Trailing yield: 2.0%. Lower than top quartile of British dividend payers (5.7%). In line with average of industry peers (2.1%). New Risk • Mar 18
New major risk - Dividend sustainability The dividend is not well covered by earnings and cash flows. The company is paying a dividend despite being loss-making. The company is paying a dividend despite having no free cash flows. Dividend yield: 2.4% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company. Tillkännagivande • Mar 14
Cosmo Pharmaceuticals N.V., Annual General Meeting, Apr 10, 2026 Cosmo Pharmaceuticals N.V., Annual General Meeting, Apr 10, 2026, at 12:00 W. Europe Standard Time. Reported Earnings • Mar 10
Full year 2025 earnings released: €0.23 loss per share (vs €8.15 profit in FY 2024) Full year 2025 results: €0.23 loss per share (down from €8.15 profit in FY 2024). Revenue: €104.2m (down 61% from FY 2024). Net loss: €3.61m (down 103% from profit in FY 2024). Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Mar 09
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to CHF92.62, the stock trades at a forward P/E ratio of 117x. Average forward P/E is 22x in the Pharmaceuticals industry in the United Kingdom. Total returns to shareholders of 77% over the past three years. Tillkännagivande • Feb 04
Cosmo Pharmaceuticals N.V. announced that it has received funding from Capital Research and Management Company Cosmo Pharmaceuticals N.V announced that it has completed a private placement with a single institutional investor and issued 937,086 treasury shares representing 5.3% of the company's outstanding shares on February 3, 2026. The transaction included participation from Small cap World Fund of the Capital Group. New Risk • Dec 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.5% average weekly change). Valuation Update With 7 Day Price Move • Dec 03
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to CHF77.70, the stock trades at a forward P/E ratio of 71x. Average forward P/E is 12x in the Pharmaceuticals industry in the United Kingdom. Total returns to shareholders of 37% over the past three years. Reported Earnings • Jul 27
First half 2025 earnings released: €0.13 loss per share (vs €4.42 profit in 1H 2024) First half 2025 results: €0.13 loss per share (down from €4.42 profit in 1H 2024). Revenue: €51.7m (down 62% from 1H 2024). Net loss: €2.01m (down 103% from profit in 1H 2024). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • May 28
Upcoming dividend of €2.05 per share Eligible shareholders must have bought the stock before 04 June 2025. Payment date: 06 June 2025. Payout ratio is a comfortable 25% and this is well supported by cash flows. Trailing yield: 3.5%. Lower than top quartile of British dividend payers (5.7%). Higher than average of industry peers (2.6%). Tillkännagivande • Apr 30
Cosmo Pharmaceuticals N.V., Annual General Meeting, May 30, 2025 Cosmo Pharmaceuticals N.V., Annual General Meeting, May 30, 2025. New Risk • Apr 15
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 51% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 51% per year for the foreseeable future. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Valuation Update With 7 Day Price Move • Apr 09
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to CHF45.15, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 11x in the Pharmaceuticals industry in the United Kingdom. Total loss to shareholders of 21% over the past three years. Tillkännagivande • Apr 01
Cosmo Pharmaceuticals N.V. Appoints Federico Sommariva as Chief Legal Counsel Cosmo Pharmaceuticals N.V. announced the appointment of Federico Sommariva as Chief Legal Counsel. Federico reports to the CEO and is member of the management team. Federico Sommariva has many years of legal and management experience in the Lifesciences industry. Since June 2013, he has worked for Gilead Sciences based in Milan (Italy), with increasing responsibilities. Most recently, he acted as Director and Global Legal Business Partner Oncology. He also served for 1.5 years as interim Head of Legal and Compliance for Gilead Sciences Romania. Federico studied law at the University of Milan and started his professional career as Legal Counsel Secondee at H&M in Rome (Italy). Reported Earnings • Mar 23
Full year 2024 earnings released: EPS: €8.15 (vs €0.31 loss in FY 2023) Full year 2024 results: EPS: €8.15 (up from €0.31 loss in FY 2023). Revenue: €266.8m (up 188% from FY 2023). Net income: €133.2m (up €138.2m from FY 2023). Profit margin: 50% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Mar 07
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CHF54.50, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 13x in the Pharmaceuticals industry in the United Kingdom. Total returns to shareholders of 2.8% over the past three years. Tillkännagivande • Feb 11
Cosmo Pharmaceuticals N.V. Announces the Appointment of Andrea Cherubini as Chief AI Officer Cosmo Pharmaceuticals N.V. announced the appointment of Andrea Cherubini as Chief AI Officer effective immediately. This important decision reflects Cosmo's commitment to integrating Artificial Intelligence as a core strategic pillar in its future growth and innovation roadmap. Andrea will report to the CEO and will be member of the executive leadership team. Andrea has been pivotal in the development and commercialization of Cosmo's GI GeniusT. As Senior Vice President - Science, AI, and Data, he was leading the development of innovative AI solutions for the Cosmo Intelligent Medical Devices division since 2018. His extensive clinical expertise, data-driven approach, and leadership in AI have already transformed patient outcomes, showcasing the real-world impact of AI in medical applications. AI as a Strategic Growth Driver In his new role as Chief AI Officer, Andrea will spearhead the expansion of AI beyond endoscopy, embedding it across Cosmo's entire portfolio to accelerate innovation, enhance efficiencies, and unlock new value for both patients and shareholders. This includes, among others: Gastroenterology Pipeline - Advancing AI applications in drug development, particularly for Bile Acid Diarrhea (BAD), to drive precision medicine and predictive analytics in GI disorders. Dermatology Pipeline - Leveraging AI to optimize clinical trial design, patient selection, and personalized treatment pathways for Breezula and other dermatological innovations. AI-Enabled Drug Discovery & Development - Expanding AI's role in R&D, regulatory strategies, and digital health applications, reinforcing Cosmo's position as a leader in AI-driven healthcare solutions. At the same time, Andrea will continue to play a critical role in shaping Cosmo's Intelligent Medical Devices division's AI roadmap, reinforcing GI GeniusT as the leading real-time AI platform in endoscopy. Tillkännagivande • Jan 08
Cosmo Pharmaceuticals N.V. to Report Fiscal Year 2024 Final Results on Mar 20, 2025 Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2024 final results at 12:00 PM, Central European Standard Time on Mar 20, 2025 Tillkännagivande • Oct 12
Cosmo Pharmaceuticals N.V. Announces Chief Financial Officer Changes Cosmo Pharmaceuticals N.V. announced the appointment of Svetlana Sigalova as its new Chief Financial Officer, effective November 11, 2024. Svetlana will succeed Niall Donnelly, who has served as CFO since 2016. Svetlana Sigalova brings a wealth of expertise from her time at Moderna, where she served as Vice President of Commercial Finance and led the financial operations for over $6 billion in global sales. Her proven ability to develop financial infrastructure and planning systems was pivotal in Moderna's rapid growth during the pandemic. Prior to Moderna, Svetlana held senior finance leadership positions at Alexion Pharmaceuticals and Vertex Pharmaceuticals, where she managed multibillion-dollar revenue streams, built high-performance finance teams, and drove operational efficiency. Niall will transition to a strategic new role as EVP - Corporate Governance & Chief Sustainability Officer, where he will report to CEO and play a key part in strengthening Cosmo's corporate governance framework and driving the Company's mission to advance environmental, social, and governance (ESG) initiatives. With a focus on achieving carbon footprint reduction and sustainable business practices, Niall's leadership will ensure Cosmo continues to build a strong and responsible organization with a robust governance structure that aligns with the Company's long-term growth and value creation. He will also remain an executive member of the Board of Directors of Cosmo. Reported Earnings • Jul 29
First half 2024 earnings released: EPS: €4.72 (vs €0.092 in 1H 2023) First half 2024 results: EPS: €4.72 (up from €0.092 in 1H 2023). Revenue: €136.2m (up 212% from 1H 2023). Net income: €76.0m (up €74.5m from 1H 2023). Profit margin: 56% (up from 3.4% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 2.7% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. New Risk • Jul 28
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 3.3% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 3.3% per year for the foreseeable future. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Upcoming Dividend • Jul 05
Upcoming dividend of €2.00 per share Eligible shareholders must have bought the stock before 10 July 2024. Payment date: 12 July 2024. The company is not currently making a profit and its cash payout ratio is 92%. Trailing yield: 2.7%. Lower than top quartile of British dividend payers (5.6%). Higher than average of industry peers (2.2%). Tillkännagivande • Apr 28
Cosmo Pharmaceuticals N.V. Announces Executive Changes at the Upcoming Annual General Meeting on 24 May 2024 Cosmo Pharmaceuticals N.V. announced the appointment of Giovanni Di Napoli as its new Chief Executive Officer, along with changes to its Board of Directors, at the upcoming Annual General Meeting (AGM) on 24 May 2024. At the same time, it will be proposed at the AGM to appoint longstanding Cosmo CEO Alessandro Della Cha as the new Chairman of Cosmo. Alessandro joined Cosmo in 2006 as member of the Board of Directors and was appointed as CEO of the Company in 2014. Giovanni is an accomplished leader with an excellent track record and joins Cosmo from Medtronic where he held various leadership positions since 2008. Until recently, Giovanni was President of Medtronic's Endoscopy Operating Unit located in Santa Clara, California. In this position, he and his team were responsible for one of the most innovative and fast-growing portfolios in the endoscopy market, which included technologies such as Endoflip, Pillcam, and GI Genius. From July 2017 to November 2020, he was Vice President and General Manager GIH - Gastrointestinal and Hepatology and was Vice President Sales U.S. - GI Solutions from February 2015 to July 2017. From April 2012 to February 2015, he was Director of Sales Marketing for Western Europe. Previously, Giovanni held various leadership positions at Johnson Johnson Medical (2001- 2010). Giovanni has an MBA from the Universita Bocconi, Milan, Italy. New Risk • Mar 24
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 21% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Dividend per share is over 28x earnings per share. Cash payout ratio: 175% Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.2% net profit margin). Tillkännagivande • Mar 22
Cosmo Pharmaceuticals N.V. to Report Fiscal Year 2023 Final Results on Apr 30, 2024 Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2023 final results on Apr 30, 2024 Reported Earnings • Mar 22
Full year 2023 earnings released: EPS: €0.071 (vs €1.05 in FY 2022) Full year 2023 results: EPS: €0.071 (down from €1.05 in FY 2022). Revenue: €96.7m (down 5.3% from FY 2022). Net income: €1.15m (down 93% from FY 2022). Profit margin: 1.2% (down from 17% in FY 2022). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Tillkännagivande • Feb 15
Cosmo Pharmaceuticals N.V. to Report First Half, 2024 Results on Jul 25, 2024 Cosmo Pharmaceuticals N.V. announced that they will report first half, 2024 results on Jul 25, 2024 Valuation Update With 7 Day Price Move • Dec 11
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to CHF48.75, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 12x in the Pharmaceuticals industry in the United Kingdom. Total loss to shareholders of 38% over the past three years. Reported Earnings • Jul 28
First half 2023 earnings released: EPS: €0.092 (vs €0.48 in 1H 2022) First half 2023 results: EPS: €0.092 (down from €0.48 in 1H 2022). Revenue: €43.7m (up 5.2% from 1H 2022). Net income: €1.49m (down 81% from 1H 2022). Profit margin: 3.4% (down from 19% in 1H 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings. Upcoming Dividend • May 24
Upcoming dividend of €1.05 per share at 2.0% yield Eligible shareholders must have bought the stock before 31 May 2023. Payment date: 02 June 2023. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 2.0%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (2.4%). Reported Earnings • Mar 24
Full year 2022 earnings released: EPS: €1.05 (vs €1.29 in FY 2021) Full year 2022 results: EPS: €1.05 (down from €1.29 in FY 2021). Revenue: €102.1m (up 57% from FY 2021). Net income: €17.2m (down 21% from FY 2021). Profit margin: 17% (down from 33% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 106% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. No independent directors (7 non-independent directors). Non-Executive Director Kevin Donovan was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Jul 28
First half 2022 earnings released First half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (up €5.74m from 1H 2021). Profit margin: (up from net loss in 1H 2021). The move to profitability was driven by lower expenses. Over the next year, revenue is forecast to grow 50% while the industry in the United Kingdom is not expected to grow. Over the last 3 years on average, earnings per share has increased by 110% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. No independent directors (7 non-independent directors). Non-Executive Director Kevin Donovan was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Breakeven Date Change • Dec 31
Forecast breakeven date pushed back to 2022 The 2 analysts covering Cosmo Pharmaceuticals previously expected the company to break even in 2021. New consensus forecast suggests the company will make a profit of €3.95m in 2022. Average annual earnings growth of 37% is required to achieve expected profit on schedule. Executive Departure • Nov 29
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 29
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 29
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 29
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 29
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 29
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 29
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 28
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 28
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 28
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 28
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 28
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 28
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 28
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 28
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 27
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 27
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 27
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 27
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 27
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 27
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 27
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 27
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 27
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 27
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 27
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 27
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 27
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 27
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 27
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 27
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 26
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 26
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 26
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 26
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 26
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 26
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 26
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 26
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 26
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 26
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 26
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 26
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 25
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 25
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 25
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 25
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 25
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 25
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 25
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Executive Departure • Nov 25
Non-Executive Director Eimear Cowhey has left the company On the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years. Breakeven Date Change • Sep 23
Forecast to breakeven in 2021 The 3 analysts covering Cosmo Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €5.22m in 2021. Earnings growth of 59% is required to achieve expected profit on schedule. Breakeven Date Change • Aug 04
Forecast breakeven moved forward to 2021 The 3 analysts covering Cosmo Pharmaceuticals previously expected the company to break even in 2022. New consensus forecast suggests the company will make a profit of €6.00m in 2021. Earnings growth of 60% is required to achieve expected profit on schedule. Reported Earnings • Aug 02
First half 2021 earnings released: €0.40 loss per share (vs €0.21 loss in 1H 2020) The company reported a soft first half result with increased losses and weaker control over costs, although revenues improved. First half 2021 results: Revenue: €28.4m (up 9.8% from 1H 2020). Net loss: €5.74m (loss widened 90% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Executive Departure • Jun 04
Non-Executive Director Hans Tanner has left the company On the 29th of May, Hans Tanner's tenure as Non-Executive Director ended. We don't have any record of a personal shareholding under Hans' name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 4.83 years. Reported Earnings • Mar 28
Full year 2020 earnings released: €0.55 loss per share (vs €1.67 loss in FY 2019) The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: €60.9m (down 2.5% from FY 2019). Net loss: €7.90m (loss narrowed 68% from FY 2019). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. 
